Citation

Malli F, Lampropoulos IC, Papagiannis D, Papathanasiou IV, Daniil Z, Gourgoulianis KI. Vaccines 2022; 10(2).

Copyright

(Copyright © 2022)

DOI

10.3390/vaccines10020337

PMID

unavailable

Abstract

The available coronavirus disease 2019 (COVID-19) vaccines have shown their effectiveness in clinical trials. We aimed to assess the real-world effects of SARS-CoV-2 vaccinations in Greece. We combined national data on vaccinations, SARS-CoV-2 cases, COVID-19-related ICU admissions and COVID-19-related deaths. We observed 3,367,673 vaccinations (30.68% of the Greek population), 278,821 SARS-CoV-2 infections and 7401 COVID-19-related deaths. The vaccination rate significantly increased from week 2 to week 6 by 85.70%, and from week 7 to 25 by 15.65%. The weekly mean of SARS-CoV-2 cases, COVID-19 ICU patients and COVID-19 deaths markedly declined as vaccination coverage accumulated. The rate of SARS-CoV-2 cases increased significantly from week 2 to week 13 by 16.15%, while from weeks 14-25 the rate decreased significantly by 13.50%. The rate of COVID-19-related ICU admissions decreased significantly by 7.41% from week 2 to week 4, increased significantly by 17.22% from weeks 5-11, then decreased significantly from weeks 17-20, by 11.99%, and from weeks 21-25, by 16.77%. The rate of COVID-19-related deaths increased significantly from week 2 to week 15 by 12.08% and decreased significantly by 16.58% from weeks 16-25. The data from this nationwide observational study underline the beneficial impact of the national vaccination campaign in Greece, which may offer control of the SARS-CoV-2 pandemic. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

Language: en

Keywords

adult; human; COVID-19; suicide; female; Greece; aged; morbidity; obesity; death; major clinical study; vaccination; intensive care unit; drug safety; demography; drug efficacy; Article; observational study; Vaccination; coronavirus disease 2019; SARS-CoV-2; SARS-CoV-2 vaccine